Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2825 Subcutaneous Injection in CD20-positive Hematological Malignancies
NCT07110194Phase 1Not yet recruiting
- Sponsor
- Chia Tai Tianqing
- Start
- Sep 2025
- Primary completion
- Mar 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tqb2825 in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL) and 1 more, sponsored by Chia Tai Tianqing. Primary endpoints: Peak time up to 4 month, Peak concentration Cmax up to 4 month and 1 more. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
tqb2825
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT07110194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07110194.